Literature DB >> 2842463

Late recurrence of testicular cancer.

N Borge1, S D Fosså, S Ous, A E Stenwig, H H Lien.   

Abstract

The aim of this study is to draw attention to important points concerning the clinical management of late relapses in testicular cancer. From 1972 to 1982 The Norwegian Radium Hospital (NRH) has treated 1,008 patients with testicular cancer. Fifteen (1.5%) of these patients relapsed 36 months or more after their primary treatment. The patients' medical records were reviewed in this retrospective study, and all available histological sections were reevaluated. Six patients had pure seminoma initially and relapsed after an average of 54.5 months. Five of them had subjective symptoms due to recurrent tumor. Four patients relapsing in the supradiaphragmatic lymph nodes only are alive with no evidence of disease after an observation time of 17 to 30 months after treatment. Nine nonseminoma patients relapsed after an average of 85 months (36 to 194 months). Eight of these were aware of subjective signs or symptoms due to recurrent tumor leading to the diagnosis of the relapse. Four of these patients are alive with no evidence of disease after an observation time of 4 to 46 months after treatment. Two of these patients relapsed with pure mature teratoma. Late relapses do occur although they are rare events. Seminoma patients relapsing in the lymph nodes only have a good prognosis, and nonseminoma patients have a slightly poorer prognosis. Active follow-up for relapse detection is not justified. All testicular cancer patients should instead be informed of typical signs and symptoms that can be related to a relapse and encouraged to seek medical help for further investigation.

Entities:  

Mesh:

Year:  1988        PMID: 2842463     DOI: 10.1200/JCO.1988.6.8.1248

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

Review 1.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

2.  Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy.

Authors:  P L Robertson; R C DaRosso; J C Allen
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

3.  Management of the post chemotherapy subcentimeter residual mass: the case for observation.

Authors:  Stephen D W Beck; Richard S Foster
Journal:  World J Urol       Date:  2009-07-15       Impact factor: 4.226

4.  Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience.

Authors:  M A Kuczyk; C Bokemeyer; C Kollmannsberger; S Corvin; A Anastasiadis; S Machtens; A Merseburger; G Wegener; A Stenze; J T Hartmann; U Jonas
Journal:  World J Urol       Date:  2004-04       Impact factor: 4.226

Review 5.  Pure seminoma: a review and update.

Authors:  Noureddine Boujelbene; Adrien Cosinschi; Nadia Boujelbene; Kaouthar Khanfir; Shushila Bhagwati; Eveleyn Herrmann; Rene-Olivier Mirimanoff; Mahmut Ozsahin; Abderrahim Zouhair
Journal:  Radiat Oncol       Date:  2011-08-08       Impact factor: 3.481

6.  Very late relapse of testicular tumour in combination with renal cancer and their retroperitoneoscopic removal.

Authors:  Mihály Murányi; Morshed Ali Salah; Béla Tállai; Mátyás Benyó; Tibor Flaskó
Journal:  Case Rep Med       Date:  2011-09-29

7.  Late recurrences of germ cell malignancies: a population-based experience over three decades.

Authors:  J Oldenburg; G C Alfsen; H Waehre; S D Fosså
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

8.  Cervical mature teratoma 17 years after initial treatment of testicular teratocarcinoma: report of a late relapse.

Authors:  Ramesh Omranipour; Mina Alavion
Journal:  World J Surg Oncol       Date:  2007-01-04       Impact factor: 2.754

9.  Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications.

Authors:  Joseph A Moore; Rebecca S Slack; Michael J Lehner; Matthew T Campbell; Amishi Y Shah; Miao Zhang; Charles C Guo; John F Ward; Jose A Karam; Christopher G Wood; Louis L Pisters; Shi-Ming Tu
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.